The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

I.b

Pneumonitis (ILD), acute and/or severe (may cause ARDS)

Publications

Patil N, Paulose RM, Udupa KS, Ramakrishna N, Ahmed T

Pulmonary Toxicity of Bleomycin - A Case Series from a Tertiary Care Center in Southern India.

Journal of clinical and diagnostic research : JCDR 2016 Apr;10;FR01-3 — 2016 Apr — FR01-3

Stein ME, Zidan J, Charas T, Gershuny A, Ben-Yosef R

Bleomycin-induced pneumonitis in three patients treated with chemotherapy for primary advanced seminoma.

Journal of B.U.ON. : official journal of the Balkan Union of Oncology 2015 May-Jun;20;928-32 — 2015 May-Jun — 928-32

Ahmed BM, Al-Zakwani IS

Incidence, outcome and predictors of bleomycin pulmonary toxicity in a university hospital in Oman.

Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2013 Mar;19;3-7 — 2013 Mar — 3-7

Rashid RS

Bleomycin lung: a case report.

BMJ case reports 2009;2009; — 2009

Ngeow J, Tan IB, Kanesvaran R, Tan HC, Tao M, Quek R, Lim ST

Prognostic impact of bleomycin-induced pneumonitis on the outcome of Hodgkin's lymphoma.

Annals of hematology 2011 Jan;90;67-72 — 2011 Jan — 67-72

Godoy MC, Nonaka D, Raphael BG, Vlahos I

Diffuse ground-glass opacities in a patient with Hodgkin lymphoma and progressive respiratory failure.

Chest 2008 Jul;134;207-12 — 2008 Jul — 207-12

Martin WG, Ristow KM, Habermann TM, Colgan JP, Witzig TE, Ansell SM

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005 Oct 20;23;7614-20 — 2005 Oct 20 — 7614-20

Sleijfer S

Bleomycin-induced pneumonitis.

Chest 2001 Aug;120;617-24 — 2001 Aug — 617-24

Maher J, Daly PA

Severe bleomycin lung toxicity: reversal with high dose corticosteroids.

Thorax 1993 Jan;48;92-4 — 1993 Jan — 92-4

White DA, Stover DE

Severe bleomycin-induced pneumonitis. Clinical features and response to corticosteroids.

Chest 1984 Nov;86;723-8 — 1984 Nov — 723-8

Bauer KA, Skarin AT, Balikian JP, Garnick MB, Rosenthal DS, Canellos GP

Pulmonary complications associated with combination chemotherapy programs containing bleomycin.

The American journal of medicine 1983 Apr;74;557-63 — 1983 Apr — 557-63

Perez-Guerra F, Harkleroad LE, Walsh RE, Costanzi JJ

Acute bleomycin lung.

The American review of respiratory disease 1972 Dec;106;909-13 — 1972 Dec — 909-13

Giaccone G, Risio M, Bonardi G, Calciati A

Stevens-Johnson syndrome and fatal pulmonary toxicity to combination chemotherapy containing bleomycin: a case report.

Tumori 1986 Jun 30;72;331-3 — 1986 Jun 30 — 331-3